Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

被引：0

作者：

Hamai, Kosuke

Masuda, Takeshi

Fujitaka, Kazunori

Suzuki, Tomoko

Matsumoto, Naoko

Matsumura, Mirai

Isoyama, Shoko

Ueno, Sayaka

Mito, Mineyo

Yamaguchi, Kakuhiro

Sakamoto, Shinjiro

Kawano, Reo

Masuda, Ken

Nishino, Ryohei

Ishikawa, Nobuhisa

Yamasaki, Masahiro

Hattori, Noboru

机构：

[1] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan

[2] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[3] JA Onomichi Gen Hosp, Dept Resp Internal Med, Onomichi, Japan

[4] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Resp Internal Med, Hiroshima, Japan

[5] Kure Med Ctr, Dept Resp Internal Med, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Hiroshima, Japan

[7] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Internal Med, Hiroshima, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21156

引用

页数：1

共 50 条

[31] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). [J].

Ahn, Myung-Ju ;

Barlesi, Fabrice ;

Felip, Enriqueta ;

Garon, Edward B. ;

Martin, Claudio Marcelo ;

Mok, Tony S. K. ;

Vokes, Everett E. ;

Ojalvo, Laureen S. ;

Koenig, Andre ;

Dussault, Isabelle ;

Paz-Ares, Luis G. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)

[32] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status [J].

Kenji Morimoto ;

Tadaaki Yamada ;

Hayato Kawachi ;

Motohiro Tamiya ;

Yoshiki Negi ;

Yasuhiro Goto ;

Akira Nakao ;

Shinsuke Shiotsu ;

Keiko Tanimura ;

Takayuki Takeda ;

Asuka Okada ;

Taishi Harada ;

Koji Date ;

Yusuke Chihara ;

Isao Hasegawa ;

Nobuyo Tamiya ;

Naoya Nishioka ;

Yuki Katayama ;

Masahiro Iwasaku ;

Shinsaku Tokuda ;

Takashi Kijima ;

Koichi Takayama .

Targeted Oncology, 2023, 18 :915-925

[33] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). [J].

Ahn, Myung-Ju ;

Barlesi, Fabrice ;

Felip, Enriqueta ;

Garon, Edward B. ;

Marcelo Martin, Claudio ;

Mok, Tony S. K. ;

Vokes, Everett E. ;

Ojalvo, Laureen S. ;

Koenig, Andre ;

Dussault, Isabelle ;

Paz-Ares, Luis G. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[34] Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1-Expressing Advanced Non-Small Cell Lung Cancer (NSCLC) [J].

Ahn, M. -J. ;

Barlesi, F. ;

Felip, E. ;

Garon, E. ;

Martin, C. M. ;

Vokes, E. ;

Koenig, A. ;

Dussault, I. ;

Ojalvo, L. S. ;

Paz-Ares, L. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) :S27-S28

[35] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status [J].

Morimoto, Kenji ;

Yamada, Tadaaki ;

Kawachi, Hayato ;

Tamiya, Motohiro ;

Negi, Yoshiki ;

Goto, Yasuhiro ;

Nakao, Akira ;

Shiotsu, Shinsuke ;

Tanimura, Keiko ;

Takeda, Takayuki ;

Okada, Asuka ;

Harada, Taishi ;

Date, Koji ;

Chihara, Yusuke ;

Hasegawa, Isao ;

Tamiya, Nobuyo ;

Nishioka, Naoya ;

Katayama, Yuki ;

Iwasaku, Masahiro ;

Tokuda, Shinsaku ;

Kijima, Takashi ;

Takayama, Koichi .

TARGETED ONCOLOGY, 2023, 18 (06) :915-925

[36] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer [J].

Jahan, N. ;

Swarup, S. ;

Sultan, A. ;

Naing, T. ;

Mogollon-Duffo, F. ;

Ball, S. ;

Tun, A. ;

Htut, T. ;

Dash, A. ;

D'Cunha, N. ;

Hardwicke, F. ;

Awasthi, S. ;

Tijani, L. ;

Thein, K. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S917-S918

[37] Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? [J].

Dempke, Wolfram C. M. ;

Fenchel, Klaus .

TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) :538-542

[38] Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab [J].

Banna, Giuseppe Luigi ;

Signorelli, Diego ;

Metro, Giulio ;

Galetta, Domenico ;

Toma, Alessandro De ;

Cantale, Ornella ;

Banini, Marco ;

Friedlaender, Alex ;

Pizzutillo, Pamela ;

Garassino, Marina Chiara ;

Addeo, Alfredo .

TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) :1533-+

[39] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status. [J].

Alessi, Joao Victor Machado ;

Ricciuti, Biagio ;

Aguilar, Elizabeth Jimenez ;

Hong, Fangxin ;

Wei, Zihan ;

Nishino, Mizuki ;

Plodkowski, Andrew J. ;

Sawan, Peter ;

Luo, Jia ;

Rizvi, Hira ;

Carter, Brett W. ;

Heymach, John ;

Altan, Mehmet ;

Hellmann, Matthew David ;

Awad, Mark M. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[40] Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec's University Teaching Hospitals (DALP-First Study) [J].

Berard, Ghislain ;

Guevremont, Chantal ;

Marcotte, Nathalie ;

Schroeder, Coleen ;

Bouchard, Nicole ;

Rajan, Raghu .

CURRENT ONCOLOGY, 2023, 30 (03) :3251-3262

← 1 2 3 4 5 →